Login
$OTLK
$0.40 +$0.01 (1.49%) After hours

$OTLK SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Oct 2026 SCHEDULE 13G
30 Sep 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

18 Sep 2026 8-K: Other Events

On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.

02 Sep 2026 Form 4: Lundquist Kevin Michael, Chief Financial Officer

Granted 500,000 Employee Stock Option (Right to Buy)

02 Sep 2026 Form 3: Lundquist Kevin Michael, Chief Financial Officer

No securities owned

27 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Executive Employment Agreement (this “Agreement”) effective as of September 1, 2026 (“Effective Date”) is entered into between Outlook Therapeutics, Inc., a Delaware corporation with its principal place of business at 111 S. Wood, A...

19 Aug 2026 SCHEDULE 13G
18 Aug 2026 10-Q
17 Aug 2026 NT 10-Q
14 Aug 2026 SCHEDULE 13D/A
14 Aug 2026 Form 4: Sukhtian Ghiath M., Director and 1 other

Bought 2,525,252 shares ($2.5M) · Acquired 2,525,252 Warrants (right to buy) (Open Market Purchase)

14 Aug 2026 Form 4: Jahr Robert Charles, Director

Bought 151,515 shares · Acquired 151,515 Warrants (right to buy) (Open Market Purchase)

14 Aug 2026 Form 4: Kenyon Lawrence A, Director

Bought 101,010 shares · Acquired 101,010 Warrants (right to buy) (Open Market Purchase)

14 Aug 2026 8-K: Other Events

Warrants to Purchase up to 55,555,556 Shares of Common Stock

14 Aug 2026 424B5
14 Aug 2026 8-K: Results of Operations and Financial Condition

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

12 Aug 2026 424B5
12 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

You should consider carefully the risks and uncertainties described below. If any of the following risks are realized, our business, financial condition, results of operations, and prospects could be adversely affected. The risks describ...

29 Jul 2026 Form 4: Sukhtian Faisal Ghiath, Director

Bought 95,398 shares ($100K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support